Tuesday, January 09, 2007

Who will buy Merck's generics?

India's Ranbaxy is interested in bidding for German chemical and pharmaceutical company Merck KGaA's generic-drug business.

But Ranbaxy may face competition from larger rivals Teva and Novartis AG, analysts said.

Teva last year bought U.S. generic-drug maker Ivax Corp. for $7.6 billion to keep the top spot, while Basel, Switzerland- based Novartis paid $8.3 billion for Hexal AG and Eon Labs Inc. in 2005.

More at Bloomberg

No comments: